Zydus Acquires US-Based Assertio Pharmaceuticals for $215 Million to Enhance Oncology Presence in America

Zydus Lifesciences to Acquire Assertio Holdings for USD 166.4 Million

Zydus Lifesciences Ltd announced on Wednesday that it will acquire US-based pharmaceutical firm Assertio Holdings for a total consideration of USD 166.4 million (approximately Rs 1,590 crore). The acquisition is set to strengthen the company's speciality and oncology footprint in the US.

The acquisition is being made through a subsidiary, Zydus Worldwide DMCC, which has signed a definitive agreement with Assertio Holdings Inc to acquire all outstanding shares of Assertio for USD 23.50 per share in cash. This represents a total consideration of approximately USD 166.4 million on a fully-diluted basis, calculated using the treasury stock method.

Assertio is a US-based pharmaceutical company focused on speciality and oncology supportive-care therapies. The acquisition provides Zydus with an established US speciality oncology commercial platform, anchored by Assertio's presence in oncology supportive care.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

The transaction represents a strategic step in strengthening Zydus' speciality and oncology footprint in the US. Assertio brings a focused commercial platform and an approved oncology asset that aligns well with Zydus' long-term strategy of building differentiated, durable speciality businesses globally.

Under the terms of the merger agreement, Zydus will commence a tender offer to acquire all outstanding shares of Assertio common stock. The transaction is structured as a tender offer to be followed by a merger, subject to customary closing conditions, including the tender of shares representing at least a majority of the total number of outstanding shares of Assertio common stock.

The tender offer is expected to commence within five business days, following the date of the merger agreement. The transaction is expected to close in the financial year 2026-27, subject to satisfaction of all closing conditions.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Note: The comparison table is not applicable in this article as the original content does not provide any revenue data or growth rates for the companies involved.